UN High-Level Meeting on TB Roundup

The first ever U.N. General Assembly’s high-level meeting (UNHLM) on tuberculosis took place on Wednesday, September 26 in New York City. The U.N. delegation of countries agreed to ambitious targets including a commitment to finding 40 million undiagnosed cases of TB by the end of 2022 and increasing annual investment in TB to $13 billion by then, too.  Endorsement of the political declaration on TB is not enough; we need to see countries bringing these commitments into action including closing the $1.3 billion annual funding gap for TB research and product development. 

TB Respiratory Chain

Submitted by barbara on

New Delhi, August 16, 2017: Johnson & Johnson Private Limited today announced a new partnership with the Institute of Microbial Technology (IMTECH), part of the Council of Scientific and Industrial Research (CSIR), to unlock the potential of Indian science and help accelerate the discovery of innovative new treatments for tuberculosis (TB).

CSIR-Institute for Microbial Technology (IMTech), Johnson & Johnson

Submitted by barbara on

CSIR-IMTech (CSIR, Institute of Microbial Technology, Government of India) has entered into a new collaboration with global pharmaceutical company, Johnson and Johnson for development of new drugs for treatment of tuberculosis (TB). The Johnson and Johnson have recently developed a “Bedaquiline” for treatment of drug-resistant TB and has been approved by several countries of world including US, Europe and India.

Stop TB Partnership and World Economic Forum Highlight "Valleys of Death" that hold back the fight against TB

In an article written by Lucica Ditiu, Executive Director, Stop TB Partnership, and Jacqueline Huh, Head, Strategic Initiatives & Innovative Financing, Stop TB, the 'valleys of death' that hold back TB new tools innovation are discussed. These two valleys occur between new tool development and commercialization and then between commercialization and roll-out. In their article, published on the World Economic Forum website, the authors discuss why innovators often fail in the pursuits of producing new tools in the fight against TB.

The Dose Podcast: Ep 1 "TB and the AMR Crisis"

The Stop TB Partnership's Working Group on New Drugs presents a new podcast series entitled "The Dose". In this series, the WGND will bring together drug developers, researchers in the TB R&D field, TB patients, global health experts, and donors to discuss, prioritize, and develop strategies to help meet the most pressing needs faced by the TB drug R&D community.

Episode 1 "TB and the AMR Crisis"

A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial of LCB01-0371.

Submitted by barbara on

This trial concluded and a published: https://www.mdpi.com/2076-3417/10/7/2211

This study is designed to explore antituberculosis of LCB01-0371 through the assess of the early bactericidal activity, safety of administration.

Treatments: 

  • Drug: LCB01-0371 800mg, QD
  • Drug: LCB01-0371 400mg, BID
  • Drug: LCB01-0371 800mg, BID
  • Drug: Tubes 3~5Tablet, QD
  • Drug: Zyvox 600mg, BID
  • Drug: LCB01-0371 1200mg, QD

Pages

Subscribe to Working Group for New TB Drugs RSS